Loading...

PSTV PLUS THERAPEUTICS INC US FDA Inspections 8-K Filing

PLS

PSTV

PLUS THERAPEUTICS INC

(PSTV)

2026 8-K

Compliance Regained

Management Change

Orphan Drug Designation

Stock Split Update

Annual Meeting Notice

Financial Results Report

Executive Compensation Update

Investor Update

Public Offering Announcement

Nasdaq Compliance Extension

Financial Results Report

Lease Agreement Signed

Compliance Update

Compliance Update

Financial Results Update

Delisting Notification

Equity Offerings

Warrant Amendments

Voluntary Delisting

Financial Statements

Delisting due to Non-Compli...

Delisting due to Non-Compli...

Authorized Common Stock Inc...

Financial Results

Nasdaq Compliance

Private Placement

Private Placement

Q3 Financial Results

Nasdaq Compliance Issue

Nasdaq Compliance Issue

Annual Meeting Results

Q2 Financial Results

Resignation of Chief Medica...

Loan Drawn and Loan Repaid

Annual Meeting Announcement

Financial Results

Securities Purchase Agreement

Presentation Slides

Financial Results Announcement

Positive Clinical Trial Dat...

Share Repurchase Program

Financial Results

Financial Results

Compliance regained with Na...

Reverse Stock Split

Annual Meeting Approval

Financial Results

No Relationship with Silico...

Entry Into a Material Defin...

Financial Results

External Links:

On April 8, 2026, Plus Therapeutics, Inc. announced that its treatment REYOBIQ™ received Orphan Drug Designation from the FDA for pediatric malignant gliomas. This is a significant event indicating regulatory support for their product.

AI Assistant

PLUS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.